Sugi Predict

Sugi Predict / Compounds / SCHEMBL4122196

SCHEMBL4122196

SCHEMBL4122196

CN[C@H]1CCN(C(=O)O)C1

nearest known ligand 0.42

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ HRH4 Q9H3N8 6/20 0.42
▸ EPHX2 P34913 6/20 0.38
▸ EPHX1 P07099 2/20 0.38
▸ MCHR1 Q99705 2/20 0.38
▸ PDK2 Q15119 1/20 0.38
▸ KDM1A O60341 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.36
▸ THRB P10828 1/20 0.35
▸ ATM Q13315 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ GHSR Q92847 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15703919 1.00 HRH4 (0.42) HRH4EPHX2EPHX1MCHR1PDK2
SCHEMBL18284105 1.00 HRH4 (0.42) HRH4EPHX2EPHX1MCHR1PDK2
Hydrochloric Acid SCHEMBL21772820 0.98 HRH4 (0.41) HRH4EPHX2EPHX1MCHR1PDK2
Hydrochloric Acid SCHEMBL6110472 0.98 HRH4 (0.41) HRH4EPHX2EPHX1MCHR1PDK2
SCHEMBL3535134 0.88 CA1 (0.45) EPHX2EPHX1ALDH1A1
SCHEMBL2030025 0.88 CA1 (0.45) EPHX2EPHX1ALDH1A1
SCHEMBL3088177 0.88 CA1 (0.45) EPHX2EPHX1ALDH1A1
SCHEMBL111634 0.87 EPHX2 (0.40) HRH4EPHX2EPHX1ALDH1A1THRB
Hydrochloric Acid SCHEMBL29280909 0.85 EPHX2 (0.39) HRH4EPHX2EPHX1ALDH1A1THRB
SCHEMBL10156614 0.85 MCHR1 (0.47) HRH4EPHX2EPHX1MCHR1PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025058008-A1 ANTIBODY-DRUG CONJUGATE CONTAINING HETEROCYCLIC COMPOUND HAVING ACTIVITY OF INDUCING DECOMPOSITION OF G12D MUTANT KRAS PROTEIN アステラス製薬株式会社 2025-03-20 — — WO disclosed
US-20240217990-A1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES, INC. 2024-07-04 — — US disclosed
CN-118239959-A Cyclopropane TLR7 and 8 inhibitor and preparation method and application thereof 上海深势唯思科技有限责任公司 2024-06-25 — — CN disclosed
CN-113788825-B Heteroaromatic compounds as VANIN inhibitors 勃林格殷格翰国际有限公司 2024-06-04 — — CN disclosed
CN-114478485-B Heteroaromatic compounds as VANIN inhibitors 勃林格殷格翰国际有限公司 2024-04-05 — — CN disclosed
US-20240067632-A1 WEE1 Degrading Compounds and Uses Thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2024-02-29 — — US disclosed
WO-2024034657-A1 PHARMACEUTICAL COMPOSITION COMPRISING HETEROCYCLIC COMPOUND アステラス製薬株式会社 2024-02-15 — — WO disclosed
WO-2024034591-A1 HETEROCYCLIC COMPOUND FOR INHIBITING AND/OR INDUCING DEGRADATION OF KRAS PROTEIN アステラス製薬株式会社 2024-02-15 — — WO disclosed
WO-2024034123-A1 PHARMACEUTICAL COMPOSITION CONTAINING HETEROCYCLIC COMPOUND アステラス製薬株式会社 2024-02-15 — — WO disclosed
EP-4294799-A2 COMPOSITIONS AND METHODS FOR INHIBITION OF RAS Theras Inc. (US) 2023-12-27 — — EP disclosed
US-20200069663-A1 HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2020-03-05 — — US disclosed
WO-2019148005-A1 INHIBITORS OF CBL-B AND METHODS OF USE THEREOF NURIX THERAPEUTICS, INC. (US) 2019-08-01 — — WO disclosed
US-20190194184-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2019-06-27 — — US disclosed
US-10246453-B2 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2019-04-02 — — US disclosed
EP-3458449-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS Xenon Pharmaceuticals Inc. (CA) 2019-03-27 — — EP disclosed
US-20170334902-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2017-11-23 — — US disclosed
WO-2017201468-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2017-11-23 — — WO disclosed
US-20090239928-A1 N-Pyrrolidin-3YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors PFIZER INC. 2009-09-24 — — US disclosed
EP-1828121-A2 N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALIN RE-UPTAKE INHIBITORS Pfizer Limited (GB) 2007-09-05 — — EP disclosed
WO-2006064336-A2 N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALIN RE-UPTAKE INHIBITORS PFIZER LIMITED (GB) 2006-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200069663-A1 HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS VHL, FANCI, PAH HRH4 290/4885EPHX2 1419/4885EPHX1 1284/4885
US-20240217990-A1 THIENOPYRROLE COMPOUNDS SSB, TPMT, LCP2 HRH4 411/4885EPHX2 2317/4885EPHX1 2462/4885
US-10246453-B2 Benzenesulfonamide compounds and their use as therapeutic agents SCN1A, SCN1B, SCN2B HRH4 1545/4885EPHX2 2484/4885EPHX1 2094/4885
US-20090239928-A1 N-Pyrrolidin-3YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors AOC3, AOC2, TPH2 HRH4 48/4885EPHX2 523/4885EPHX1 677/4885
US-20170334902-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B HRH4 1545/4885EPHX2 2484/4885EPHX1 2094/4885
US-20240067632-A1 WEE1 Degrading Compounds and Uses Thereof WEE1, WEE2, PPME1 HRH4 4319/4885EPHX2 2360/4885EPHX1 1924/4885
US-20190194184-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B HRH4 1875/4885EPHX2 2242/4885EPHX1 1976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.